Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Leases (2020 - 2026)

10x Genomics' Current Leases history spans 6 years, with the latest figure at $11.0 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 18.3% to $11.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.0 million, a 18.3% increase, with the full-year FY2025 number at $11.0 million, up 18.3% from a year prior.
  • Current Leases hit $11.0 million in Q4 2025 for 10x Genomics, up from $10.5 million in the prior quarter.
  • Over the last five years, Current Leases for TXG hit a ceiling of $11.5 million in Q4 2023 and a floor of $4.5 million in Q3 2021.
  • Historically, Current Leases has averaged $8.7 million across 5 years, with a median of $9.3 million in 2023.
  • Biggest five-year swings in Current Leases: skyrocketed 88.02% in 2022 and later fell 19.4% in 2024.
  • Tracing TXG's Current Leases over 5 years: stood at $5.1 million in 2021, then soared by 76.13% to $9.0 million in 2022, then increased by 27.49% to $11.5 million in 2023, then dropped by 19.4% to $9.3 million in 2024, then increased by 18.3% to $11.0 million in 2025.
  • Business Quant data shows Current Leases for TXG at $11.0 million in Q4 2025, $10.5 million in Q3 2025, and $9.7 million in Q2 2025.